BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-01-29 23:27 |
BERGENBIO ASA - PRIVATE PLACEMENT SUCCESSFULLY PLACED
|
English | 14.1 KB | ||
| 2020-01-29 15:30 |
BERGENBIO ASA - CONTEMPLATED PRIVATE PLACEMENT
|
English | 111.6 KB | ||
| 2020-01-29 15:30 |
BERGENBIO ASA - CONTEMPLATED PRIVATE PLACEMENT
|
English | 15.7 KB | ||
| 2020-01-15 16:10 |
BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL IN…
|
English | 232.0 KB | ||
| 2020-01-15 16:10 |
BERGENBIO MEETS EFFICACY ENDPOINT for FIRST STAGE OF PHASE II TRIAL WITH AXL IN…
|
English | 6.5 KB | ||
| 2019-12-12 10:19 |
Financial calendar
|
English | 762 bytes | ||
| 2019-12-09 06:00 |
BerGenBio presents preliminary clinical data from Phase II combination trial of…
|
English | 108.5 KB | ||
| 2019-12-09 06:00 |
BerGenBio presents preliminary clinical data from Phase II combination trial of…
|
English | 8.6 KB | ||
| 2019-11-19 06:00 |
BerGenBio ASA: Results for the third quarter 2019
|
English | 11.5 MB | ||
| 2019-11-19 06:00 |
BerGenBio ASA: Results for the third quarter 2019
|
English | 240.1 KB | ||
| 2019-11-19 06:00 |
BerGenBio ASA: Results for the third quarter 2019
|
English | 8.8 KB | ||
| 2019-11-08 12:00 |
BerGenBio presents updated phase 2 NSCLC clinical and translational data for be…
|
English | 216.9 KB | ||
| 2019-11-08 12:00 |
BerGenBio presents updated phase 2 NSCLC clinical and translational data for be…
|
English | 9.7 KB | ||
| 2019-11-07 11:33 |
BerGenBio to present clinical data from Phase II combination trial of bemcentin…
|
English | 138.6 KB | ||
| 2019-11-07 11:33 |
BerGenBio to present clinical data from Phase II combination trial of bemcentin…
|
English | 4.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
